Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC-Reference-Cited by-同舟云学术

Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC

Published:2022-01-01 Issue:1 Volume:12 Page:16-19
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:

Author:

Lim Sun Min¹,Kim Chang Gon¹,Lee Jii Bum¹²^ORCID,Cho Byoung Chul¹^ORCID

Affiliation:

1. 1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

2. 2Division of Hemato-oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.

Abstract

Abstract Summary: HER3 is ubiquitously expressed in EGFR-mutant non–small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne and colleagues highlight early clinical data supporting patritumab deruxtecan as a potentially appreciable agent for previously treated EGFR-mutant NSCLC. See related article by Jänne et al., p. 74.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Link

https://aacrjournals.org/cancerdiscovery/article-pdf/12/1/16/3020026/16.pdf

Reference10 articles.

1. Toward personalized treatment approaches for non-small-cell lung cancer;Wang;Nat Med,2021

2. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

3. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review;Piper-Vallillo;J Clin Oncol,2020

4. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M;Thress;Nat Med,2015

5. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study;Sequist;Lancet Oncol,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer;Proceedings of the National Academy of Sciences;2024-05-30

2. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors;Journal of Translational Medicine;2024-04-17

3. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-02

4. Targeting HER3 to overcome EGFR TKI resistance in NSCLC;Frontiers in Immunology;2024-01-04

5. Targeted therapy for lung cancer: Beyond EGFR and ALK;Cancer;2023-04-19